Publications by authors named "M Martin-Ordiales"
Unlabelled: Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by the presence of two pathogenic variants in the LDLR, APOB, PCSK9 or LDLRAP1 genes, which cause very high levels of LDL cholesterol and premature atherosclerotic cardiovascular disease (ASCVD).The objective of this study is to analyze the current situation regarding diagnosis, cardiovascular disease, lipid-lowering treatment and degree of control of lipids in patients with HoFH in the National Dyslipidemia Registry of the Spanish Atherosclerosis Society.
Methods: Subjects with HoFH, confirmed by the presence of two pathogenic variants in the genes mentioned above, included in the registry from 2013 to June 2023 with an updated review were analyzed.
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
Atherosclerosis
June 2024
Article Synopsis
- The study focuses on the characteristics and long-term outcomes of patients with homozygous familial hypercholesterolemia (HoFH), a severe genetic condition affecting cholesterol levels and cardiovascular health.
- Data was collected from the SAFEHEART study between 2004 and 2022, analyzing 39 HoFH patients with a median follow-up of 11 years, revealing significant genetic and clinical variations among them.
- Results showed a high initial level of LDL cholesterol (median 555 mg/dL), but treatment greatly improved this (median 122 mg/dL), which also led to a reduction in atherosclerotic cardiovascular disease (ASCVD) events over time.
Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
Eur J Prev Cardiol
March 2023
Article Synopsis
- * Out of 696 patients studied, a high persistence rate of 96.1% with PCSK9i treatment was observed over a median follow-up of 3.7 years, leading to significant reductions in LDL-C levels.
- * The treatment not only improved cholesterol management, with 77% reaching 2016 LDL-C goals, but also maintained a good quality of life for the patients throughout the study period.
Objective: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare.
Methods: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab.
Results: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males.